Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Promising immuno-oncology strategies for melanoma: LAG3, STING, RIG-I, TLR

Thomas Gajewski • 19 Oct 2018
ESMO 2018
Melanoma

Immunotherapy for melanoma has taken off, opening the door to a new era of therapy. Here, Thomas Gajewski, MD, PhD, of the University of Chicago Comprehensive Cancer Center, Chicago, IL, discusses new immuno-oncology strategies to improve therapy further, including potential targets following resistance to PD-1/PD-L1 inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Thomas Gajewski

Melanoma highlights from ESMO 2018
1:45
Melanoma highlights from ESMO 2018
Thomas Gajewski • 19 Oct 2018
Investigating the tumour microenvironment for immunotherapy in melanoma
1:36
Investigating the tumour microenvironment for immunotherapy in melanoma
Thomas Gajewski • 19 Oct 2018

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals